.jpg&contenttype=jpeg)
Nanocoating for stents: prevention of coronary re-stenosis
Recent studies show that drug-eluting-stents perform superior than bare metal stents in the treatment of high-risk cardiac patients. At ComPaMED 2007, the Germany based company HEMOTEQ, leading designer and manufacturer of ultra-thin coatings for medical devices, presented their solutions for customized coating of stents.
Hemoteq’s Ouverture® is a high-perfomance drug-eluting stent platform designed for the most effective treatment of coronary stenosis and the prevention of re-stenosis.
The new product-line consists of two different models:
- The Repulsion® coating features an optimized, smart drug eluting matrix that has been designed to ensure the controlled and safe release for a wide range of potent drugs. The coating is fully biodegradable, biocompatible and hemocompatible.
- The Camouflage® coating has unique thrombo-protective features. It outperforms bare 316L stents in antirestenotic protection due to less coronary injury. A covalently bonded synthetic carbohydrate masks the stent’s surface as endothelial cells (biomimicry), resulting in outstanding hemocompatibility.
Both Ouverture-coatings could be adapted to virtually any metallic stent material and design. They are also adaptable to most hydrophobic, hydrophilic or amphiphilic drugs.
This article was published on 11/16/2007